Does The Street Have Neogen Figured Out?

Before you go, we thought you'd like these...
Before you go close icon

Neogen (NAS: NEOG) is expected to report Q3 earnings on March 26. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Neogen's revenues will increase 13.8% and EPS will grow 31.8%.

The average estimate for revenue is $51.1 million. On the bottom line, the average EPS estimate is $0.29.


Revenue details
Last quarter, Neogen booked revenue of $50.7 million. GAAP reported sales were 13% higher than the prior-year quarter's $44.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, EPS came in at $0.28. GAAP EPS of $0.28 for Q2 were 27% higher than the prior-year quarter's $0.22 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 53.8%, 330 basis points better than the prior-year quarter. Operating margin was 20.6%, 250 basis points better than the prior-year quarter. Net margin was 13.4%, 170 basis points better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $205.1 million. The average EPS estimate is $1.13.

Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 245 members out of 254 rating the stock outperform, and nine members rating it underperform. Among 57 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 57 give Neogen a green thumbs-up, and give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Neogen is outperform, with an average price target of $47.25.

Is Neogen the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.

The article Does The Street Have Neogen Figured Out? originally appeared on Fool.com.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners